A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Clinical needs of patients with disabilities are seen with the “medical gaze,” a depersonalized lens of evidence-based medicine and of presumed objectivity.
AMA J Ethics. 2023;25(1):E85-87. doi:
10.1001/amajethics.2023.85.
Professor Katie Watson joins Ethics Talk to discuss what clinicians need to know about changes to the post-June 2022 legal, ethical, and clinical landscape of abortion care in the US.
Professor Katie Watson joins Ethics Talk to consider key questions about clinical and legal risk management for clinicians trying keep patients safe and for patients with complex pregnancies trying to stay alive.
Dr Isa Ryan joins Ethics Talk to discuss her article, coauthored with Dr Ashish Premkumar and Professor Katie Watson: “Why the Post-Roe Era Requires Protecting Conscientious Provision as We Protect Conscientious Refusal in Health Care.”
The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions.
Refusal of pediatric euthanasia can be considered iatrogenic insofar as it inadvertently prolongs patient suffering, but attitudes differ cross-culturally.
AMA J Ethics. 2017;19(8):802-814. doi:
10.1001/journalofethics.2017.19.8.msoc1-1708.